GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Accumulated other comprehensive income (loss)

NervGen Pharma (TSXV:NGEN) Accumulated other comprehensive income (loss) : C$17.21 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. NervGen Pharma's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was C$17.21 Mil.

NervGen Pharma's quarterly Accumulated other comprehensive income (loss) increased from Jun. 2023 (C$14.21 Mil) to Sep. 2023 (C$15.89 Mil) and increased from Sep. 2023 (C$15.89 Mil) to Dec. 2023 (C$17.21 Mil).

NervGen Pharma's annual Accumulated other comprehensive income (loss) increased from Dec. 2021 (C$9.46 Mil) to Dec. 2022 (C$11.82 Mil) and increased from Dec. 2022 (C$11.82 Mil) to Dec. 2023 (C$17.21 Mil).

NervGen Pharma Accumulated other comprehensive income (loss) Historical Data

The historical data trend for NervGen Pharma's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Accumulated other comprehensive income (loss) Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial 1.68 5.30 9.46 11.82 17.21

NervGen Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.82 12.28 14.21 15.89 17.21

NervGen Pharma Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

NervGen Pharma Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma (TSXV:NGEN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
XCNQ:DTC TSX:EPRX TSX:BCT NEOE:MMED XCNQ:MSET TSX:ONC TSXV:ARCH TSXV:MIR TSXV:DMT TSX:HBP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
NGENF:USA 9UA:Germany
Address
2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6
Website
https://www.nervgen.com
NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.
Executives
John Ruffolo Director

NervGen Pharma (TSXV:NGEN) Headlines

No Headlines